PharmaFocus Today – Page 29 – media

Jianjia Robot applies to withdraw its IPO application documents

On September 26th, the Shanghai Stock Exchange announced that Hangzhou Jianjia Robot Technology Co., Ltd. (hereinafter referred to as Jianjia Medical) has applied to withdraw its application for listing and therefore decided to terminate the review of its public offering of shares and listing on the Science and Technology Innovation Board. It is reported that Jianjia Robot applied for an IPO on the Science and Technology Innovation Board on April 2, 2023. After a round of inquiries, the Shanghai Stock Exchange reviewed and focused on issues such as orthopedic and dental implant surgical robots, market space, and core technologies. It takes one and a half years from application to termination. Yesterday, Jianjia Robot terminated its IPO, and another equipment company’s attempt to go public failed. The winter of IPO for equipment companies continues. When will spring come? Jianjia Robot has great potential for the future Jianjia Robot was founded in ...
- Source: drugdu
- 100
- September 30, 2024
What Are Its Treatment Prospects?

Recently, according to publicly available information from the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the technetium-99m ([99mTc]) hydrazinonicotinamide polyethylene glycol RGD peptide injection (referred to as “99mTc-3PRGD2”) developed by Ruidiao Pharmaceuticals has been included in the priority review list. This also applies to the injection of toluenesulfonate hydrazone nicotinamide polyethylene glycol RGD peptide. 99mTc-3PRGD2 is a radiolabeled drug conjugate (RDC) independently developed by Ruidiao Pharmaceuticals. It is the first class I new drug for radiologic diagnosis in nuclear medicine in China and the world’s first broad-spectrum tumor imaging agent for SPECT imaging. Notably, the success of this drug’s development will change the current technical status and conventional understanding that SPECT/CT imaging technology in nuclear medicine cannot be used for tumor diagnosis, staging, and efficacy evaluation. According to Ruidiao Pharmaceuticals, 99mTc-3PRGD2 targets integrin and specifically binds to the integrin αvβ3 receptor on tumor neovascularization, demonstrating high ...
- Source: drugdu
- 83
- September 30, 2024
The second half of the battle to defend the Medicine King

Recently, Astellas announced that Japan’s MHLW has approved its ADC drug ennozumab PADCEV and Merck’s K drug as a first-line combination therapy for adult patients with fundamentally unresectable urothelial cancer. With excellent data, this combination treatment regimen was approved by the Japanese MHLW in such a short time after Merck announced on September 4 that it had been approved by the European Commission (EC) as a first-line therapy. However, sporadic victories cannot conceal the plight of K-drugs. For the pharmaceutical industry, the biggest hot spot in the past two weeks is definitely the announcement by Kangfang Biologics on September 8 that ivocilimab has become the world’s first and only single-drug head-to-head phase III clinical study to prove that its efficacy is significantly better than that of pabrolib. The drug Zizumab. On the day the results were announced, Merck’s stock price fell in response, and the dilemma was obvious. Under the ...
- Source: drugdu
- 85
- September 30, 2024
A historic night in the treatment of schizophrenia

On September 26, the field of schizophrenia ushered in a historic moment, when KarXT developed by Karuna was approved by the FDA for marketing. This means that Bristol-Myers Squibb’s tens of billions of bets have succeeded in their first battle. On December 22 last year, Bristol-Myers Squibb spent $14 billion to acquire Karuna for KarXT. KarXT has been approved for marketing, and there is another winner – Zai Lab. Currently, Zai Lab owns the rights to KarXT in Greater China. Considering that there are more than 8 million schizophrenia patients in China, and the introduction cost of Zai Lab is not high, it is expected to obtain sufficient profits. Of course, all this can only be said to have settled, and is not surprising. Most of the existing schizophrenia treatments are old varieties approved in the 1990s. KarXT does not rely on dopaminergic or serotonergic pathways and is the first ...
- Source: drugdu
- 69
- September 30, 2024
From the rise of Sinocell, we can see the first principles of pharmaceutical companies

In the 1950s, George W. Merck, then CEO of Merck, said a widely circulated saying in the pharmaceutical industry: “We should always remember that drugs are produced for humans, not for the pursuit of profits. As long as we stick to this belief, profits will follow.” It is true. Looking at large overseas pharmaceutical companies, the key to their success lies in patient-centeredness and a strong sense of social responsibility. In China, there are more and more such examples. For example, the vision of Sinocell is to focus on the research and development of drugs urgently needed by the people and provide patients with high-quality and affordable biological drugs. It seems to coincide with Merck. On the product side, Sinocell uses technological innovation to provide higher quality and lower cost drugs, which reduces the economic burden of domestic patients, while bringing better treatment effects and achieving a win-win situation of ...
- Source: drugdu
- 77
- September 30, 2024
Fosun Pharma continues to strengthen the research and development of innovative cancer drugs, and will build the most comprehensive cell therapy pipeline in Pudong

Cell therapy brings a paradigm revolution that can bring hope for a cure to cancer patients. The first cell therapy product to be launched is Yikaida ® It’s a good example. Cell therapy is a key focus of Fosun Pharma’s future development During a recent interview with Zhang Wenjie, CEO and Chairman of Fosun Pharma, he stated that Fosun Pharma is focusing on niche markets with broad prospects in the pharmaceutical industry. Just this month, Fosun Pharma announced that it will fully control Fosun Kate, which is planning to be renamed Fosun Carey and will serve as Fosun Pharma’s core platform in the field of cell therapy technology, continuing to focus on the field of tumor immunotherapy. It is reported that Fosun Kate, located in Pudong, is planning to build the strongest and most comprehensive cell therapy pipeline in China and even globally. Building a powerful CAR-T product pipeline In ...
- Source: drugdu
- 93
- September 29, 2024
Chinese scientists release transcriptome map of single-cell space in the cerebellar cortex across species

The cerebellum plays a crucial role in motor and cognitive functions, with region specific functional connections between its cortex and various sensory motor and associative regions of the neocortex. However, compared to the cerebral cortex, the various regions of the cerebellar cortex have relatively uniform cellular structures and typical local circuits, which makes the complexity of how cellular tissue supports cerebellar connections and functions an important issue. Figure 1: Composition of neurons in the cerebellar cortex (Image reference from: https://vanat.ahc.umn.edu/neurLab6/Circuits.html ） In recent years, the development of single-cell omics has driven multiple studies on the composition of cerebellar cells, but previous research on the molecular and functional diversity of cerebellar cortical cells has mainly been based on the mouse cerebellum. The cerebellum of primates has significantly expanded during evolution, with an increase in the number of neurons and more complex cognitive functions. Therefore, determining the existence of primate specific cell ...
- Source: drugdu
- 92
- September 29, 2024
Actively Exploring New Paths for Investment and Mergers, Potential New Drug Commercialization is Imminent

Recently, Sanyuan Gene, a company listed on the Beijing Stock Exchange, stated in discussions with investors that it will adhere to the principle of “prudent research and steady advancement.” The company aims to explore pathways for external investment and mergers centered around its main business direction. It plans to fully utilize various tools and platforms within the capital market to seek high-quality investment or merger targets that can synergistically develop across research, production, and sales, with the goal of achieving higher quality development in both serious medicine and therapeutic medicine markets. In the pharmaceutical sector, the development of innovative drug companies is a critical component of new productive forces and is receiving significant attention from capital markets. As a national-level specialized “little giant” enterprise, Sanyuan Gene has been deeply involved in the biopharmaceutical field for 32 years. Since its listing on the Beijing Stock Exchange, the company has actively responded ...
- Source: drugdu
- 103
- September 29, 2024
Pfizer and Shanghai Pharmaceuticals Reach Strategic Cooperation to Create High-Quality Preventive Immunization Services

On September 26, Pfizer Investment Co., Ltd. (referred to as Pfizer) and Shanghai Pharmaceuticals Holding Co., Ltd. (referred to as Shanghai Pharmaceuticals) signed a strategic cooperation framework agreement. The two parties will focus on the vaccine field, engaging in long-term collaboration in product promotion, the introduction of innovative products, and policy research. Leveraging their respective strengths, they will explore strategies to deepen and enhance their partnership in the commercial promotion of vaccine products and accelerate the introduction of innovative products, along with thorough cooperation in policy research and capacity training. This effort aims to support the robust development of China’s public health services and disease control efforts, ultimately aiding disease prevention and health improvement across all stages of life. Jean-Christophe Pointeau, President of Pfizer China, stated: “The collaboration between Pfizer and Shanghai Pharmaceuticals will harness both parties’ strengths to empower the promotion and dissemination of innovative vaccines scientifically, allowing internationally ...
- Source: drugdu
- 79
- September 29, 2024
Domestic ultrasonic scalpel industry enters “life and death situation”

In a recent survey of front-line practitioners in the ultrasonic scalpel industry, the most common answer was that the industry is going through a period of pain. The general consensus is that domestic brands will undergo a major reshuffle this year and next. Zhang Tao, founder of Ansukang, believes that from the first domestic ultrasonic scalpel certification in 2013 to 2023, it took about ten years for domestic brands to develop from scratch. Next, domestic brands are moving towards a new stage from existence to excellence. Half sea water, half fireworks. Judging from the data on paper, the domestic ultrasonic scalpel market will see rapid growth in sales in 2023. According to data recently released by a market research institution, domestic ultrasonic scalpels (excluding the blade) are increasing rapidly and have reversed the import monopoly. But when Artery.com used data to explore the drivers of growth from front-line personnel in ...
- Source: drugdu
- 86
- September 29, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.